Ruixing Zhang

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato et al. · BMJ · 2024 · 245 citations · Full text

Medicine, Oncology, Pharmacology +17

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Lin Shen, Yanqiao Zhang, Ziyu Li et al. · Nature Medicine · 2025 · 81 citations

Medicine, Oncology, Pharmacology +11

A polymorphism at the miR‐502 binding site in the 3′‐untranslated region of the histone methyltransferase <i>SET8</i> is associated with hepatocellular carcinoma outcome

Zhanjun Guo, Chensi Wu, Xiaoling Wang et al. · International Journal of Cancer · 2011 · 64 citations · Full text

Medicine, Genetics, Molecular Biology +17

Sirtuin-3 (SIRT3) expression is associated with overall survival in esophageal cancer

Yue Zhao, Huichai Yang, Xiaoling Wang et al. · Annals of Diagnostic Pathology · 2013 · 51 citations

Medicine, Cancer Biology, Oncology +14

Sequence polymorphisms of mitochondrial D-loop and hepatocellular carcinoma outcome

Cui-ju Wang, Fengbin Zhang, Haiyan Fan et al. · Biochemical and Biophysical Research Communications · 2011 · 49 citations

Medicine, Genetics, Molecular Genetics +15